Litts Drug Eruption & Reaction Database - Presented by CRC Press

Nothing else can remotely compare to it.Patricia Wong, MD, Stanford University Medical Centre


Log in
In order to deliver a personalised, responsive service and to improve the site, we remember and store information about how you use it. This is done using simple text files called cookies which sit on your computer. By continuing to use this site and access its features, you are consenting to our use of cookies. To find out more about the way drugeruptiondata.com uses cookies please read our 'Cookie Policy'.
Continue
Menu
Login
  • Home
  • About About
    • About the Database
    • About the Book
    • Related Products
    • About Dr Litt
    • About Dr Shear
  • Alerts
  • Litt’s App
  • Contact Us
  • Help
  • Subscribe Subscribe
    • Individual Subscription
    • Institutional Subscription

Drugs belonging to  restart save

class – Antineoplastic / anticancer agent (see also Immune checkpoint inhibitor) – 71 items found

  • show all
  • 0–9
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Anastrozole

Arsenic

Asparaginase

Asparaginase Erwinia chrysanthemi

Atezolizumab

Avelumab

Azacitidine

Bexarotene

Cabazitaxel

Capecitabine

Carboplatin

Cemiplimab

Cetuximab

Cisplatin

Cladribine

Cytarabine

Dacarbazine

Dasatinib

Decitabine

Denileukin


Loading more results

No more results to show

Adverse reactions attributed to entire drug class 'Antineoplastic / anticancer agent (see also Immune checkpoint inhibitor)'

Please login to view adverse reactions.

Flagellate dermatitis

    • (2022): Constantinou A+, Skin Health Dis 2(1), e92 (54 cases) [REVIEW]

Hyperkeratosis

    • (2020): Vastarella M+, Drug Saf Jan, Epub ahead of print [REVIEW]

Hypersensitivity

    • (2023): Galateanu B+, Int J Mol Sci 24(4), 3886 [REVIEW]

Leg ulceration

    • (2025): Rousselot M+, J Wound Care 34(3), 250-254 (45 cases)

Photosensitivity

    • (2024): Fattore D+, Ital J Dermatol Venerol Jun, Online ahead of print [REVIEW]

Pigmentation (Skin)

    • (2024): Shan J+, Arch Dermatol Res 316(6), 215 [REVIEW]

Toxic erythema of chemotherapy (TEC)

    • (2023): Nguyen CV+, JAMA Dermatol 159(2), 219-222 (6 cases)
    • (2021): Ríos-Viñuela E+, Acta Derm Venereol 101(4), adv00429 (45 cases) (localized epidermal necrolysis at the infusion site classified as "localized injection-site TEC")

Alopecia / hair loss

    • (2024): Aoyama Y+, Breast Cancer 31(2), 234-242 (Chemotherapy-Induced Alopecia Distress Scale )
    • (2024): Kraehenbuehl L+, Support Care Cancer 32(6), 369 (Chemotherapy-Induced Alopecia Distress Scale )
    • (2022): Hrin ML+, J Am Acad Dermatol 86(6), 1434-1435 [REVIEW]
    • (2018): Dunnill CJ+, Oncologist 23(1), 84-96
    • (2011): Miteva M+, Am J Dermatopathol 33(4), 345-50 (10 cases)

Burning Mouth Syndrome / glossodynia / glossalgia / glossopyrosis (also includes stomatodynia / oral dysesthesia / stomatopyrosis)

    • (2021): Hino S+, Ann Maxillofac Surg 11(1), 86-90 (15 cases)

Stomatitis (oral mucositis)

    • (2023): Śledzińska A+, Cancer Invest Mar, Online ahead of print [REVIEW]

Ulcerative stomatitis

    • (2021): Satheeshkumar PS+, Int J Med Inform Aug, Online ahead of print [REVIEW]

Atrial fibrillation

    • (2024): Tamargo J+, Pharmacol Res Jan, Online ahead of print [REVIEW]

Bradycardia / sinus bradycardia

    • (2022): Tamargo J+, Drug Saf Jan, Online ahead of print [REVIEW]

Capillary leak syndrome

    • (2022): Izzedine H+, Kidney Int Rep 7(5), 945-953 [REVIEW]

Cardiomyopathy

    • (2025): Fazzini L+, J Clin Med 14(4), 1286 [REVIEW] (pharmacogenomics)

Cardiotoxicity

    • (2025): Chan SHY+, Cancers (Basel) 17(2), 311 (pharmacovigilance / pharmacoepidemiology)
    • (2024): Jaiswal V+, Medicina (Kaunas) 60(4), 580 [REVIEW] (cardioprotective benefits associated with concomitant statin therapy)
    • (2023): Qu Y+, Drug Discov Today Sep, Online ahead of print (association)

Anosmia (smell loss) / smell disorder

    • (2023): Debbaneh P+, Auris Nasus Larynx Jan, Online ahead of print (association)

Dysgeusia (taste perversion)

    • (2021): Hino S+, Ann Maxillofac Surg 11(1), 86-90 (12 cases)

Leukoencephalopathy / posterior reversible encephalopathy syndrome (PRES)

    • (2024): Lei CL+, Expert Opin Drug Saf Mar, Online ahead of print (pharmacovigilance)

Peripheral neuropathy

    • (2025): Belsky JA+, Support Care Cancer 33(4), 350 [REVIEW]Pediatric
    • (2025): Jiang J+, Cancer Lett Mar, Online ahead of print [REVIEW]
    • (2025): Yanbing L+, World J Surg Oncol 23(1), 77 [REVIEW]
    • (2024): Tao Z+, Cancer Lett Dec, Online ahead of print [REVIEW]
    • (2022): Tay N+, Front Mol Biosci Oct (e-Collection) [REVIEW]Pediatric
    • (2021): Hino S+, Ann Maxillofac Surg 11(1), 86-90 (13 cases)
    • (2021): Hung HW+, Int J Environ Res Public Health 18(11), 5677
    • (2021): Inoue M+, Sci Rep 11(1), 11324 [REVIEW]
    • (2021): Li T+, Neurol Sci 42(10), 4109-4121 [REVIEW]
    • (2021): Selvy M+, Support Care Cancer 29(7), 4033-4043
    • (2011): Balayssac D+, Expert Opin Drug Saf 10(3), 407-17 [REVIEW]

Hypothyroidism

    • (2022): Deligiorgi MV+, Expert Rev Clin Pharmacol Jun, Online ahead of print [REVIEW]

Diarrhea

    • (2022): Okunaka M+, Int J Mol Sci 23(20), 12407

Esophagitis

    • (2022): Abdi S+, Gastroenterol Hepatol Bed Bench 15(3), 219-224 [REVIEW]

Gastrointestinal adverse reaction

    • (2022): Akbarali HI+, Adv Cancer Res 155, 131-166 [REVIEW]
    • (2021): Kawasumi K+, Mol Clin Oncol 14(1), 12

Hepatotoxicity / liver injury / acute liver injury / drug-induced liver injury (DILI)

    • (2025): Chodup P+, Liver Int 45(2), e70002 [REVIEW]
    • (2022): Sanguanboonyaphong P+, Asian Pac J Cancer Prev 23(1), 93-100Pediatric
    • (2021): Kong X+, Br J Clin Pharmacol May, Online ahead of print [REVIEW]

Nausea

    • (2022): Sanguanboonyaphong P+, Asian Pac J Cancer Prev 23(1), 93-100Pediatric

Neutropenic enterocolitis

    • (2024): Amanati A+, J Oncol Pharm Pract Mar, Online ahead of print (pharmacovigilance)

Pneumatosis intestinalis / pneumatosis cystoides intestinalis

    • (2022): Gazzaniga G+, Cancers (Basel) 14(7), 1666 [REVIEW]

Vomiting

    • (2022): Sanguanboonyaphong P+, Asian Pac J Cancer Prev 23(1), 93-100Pediatric

Gonadotoxicity

    • (2024): Gentile G+, Cancer Treat Rev Jul, Online ahead of print [REVIEW]

Ovarian injury /ovarian damage

    • (2024): Tanaka Y+, Curr Oncol Rep Nov, Online ahead of print [REVIEW]
    • (2023): Bhardwaj JK+, J Biochem Mol Toxicol 37(7), e23371, Online ahead of print [REVIEW]

Ovarian injury /ovarian damage

    • (2024): Zha Y+, Zhejiang Da Xue Xue Bao Yi Xue Ban May, Online ahead of print [REVIEW]
    • (2011): Hancke K+, Support Care Cancer 19(12), 1909-19 [REVIEW]
    • (2001): Blumenfeld Z, J Soc Gynecol Investig 8(1 Suppl Proceedings), S60-4
    • (1996): Bines J+, J Clin Oncol 14(5), 1718-29
    • (1996): Blumenfeld Z+, Hum Reprod 11(8), 1620-6

Anemia

    • (2022): Sanguanboonyaphong P+, Asian Pac J Cancer Prev 23(1), 93-100Pediatric

Neutropenia (neutrophils decreased)

    • (2023): Mohanlal R+, Cancer Invest Mar, Online ahead of print [REVIEW]
    • (2022): Sanguanboonyaphong P+, Asian Pac J Cancer Prev 23(1), 93-100Pediatric

Thrombocytopenia / platelets decreased

    • (2023): Zhou S+, Sci Rep 13(1), 3185
    • (2022): Sanguanboonyaphong P+, Asian Pac J Cancer Prev 23(1), 93-100Pediatric

Corneal neuropathic changes

    • (2021): Chiang JCB+, Ocul Surf 21, 221-237 [REVIEW]

Ocular adverse effect

    • (2022): Sakellakis M+, Cureus 14(7), e27266 [REVIEW]

Nephrotoxicity / kidney injury / acute kidney injury (AKI) / drug-induced kidney injury

    • (2024): Connor S+, Drug Discov Today Mar, Online ahead of print [REVIEW]
    • (2024): Yoon SY+, Sci Rep Jul (e-Collection) (pharmacovigilance / pharmacoepidemiology)
    • (2022): Rey A+, Fundam Clin Pharmacol Jan, Online ahead of print

Interstitial lung disease / interstitial pneumonitis / interstitial pneumonia (cryptogenic organizing pneumonia) / drug-induced interstitial lung disease

    • (2025): Hwang IH+, Expert Opin Drug Saf Feb, Online ahead of print [REVIEW] (pharmacovigilance / pharmacoepidemiology)
    • (2024): Jiang T+, Ther Adv Drug Saf Jan (e-Collection) (pharmacovigilance)
    • (2024): Ma Z+, Expert Opin Drug Saf Feb, Online ahead of print [REVIEW]
    • (2024): Oishi K+, Respir Med, 107924
    • (2023): Dai HP+, Curr Med Sci 43(1), 1-12 [REVIEW]
    • (2022): Zhonghua Zhong Liu Za Zhi (Chinese) 44(7), 693-702 [REVIEW]
    • (2022): Conte P+, ESMO Open 7(2), 100404
    • (2022): Miyagahara T+, Asia Pac J Clin Oncol Dec, Online ahead of print6%

Pneumonitis

    • (2024): Oishi K+, Respir Med Dec, Online ahead of print (interstitial lung abnormalities and other associated risk factors)

Pulmonary fibrosis

    • (2024): McCall KL+, Pharmacoepidemiol Drug Saf 33(5), e5797 (association) (pharmacovigilance / pharmacoepidemiology)

Pulmonary toxicity

    • (2025): Belluzzi L+, Breast Cancer (Dove Med Press) 17, 53-66 [REVIEW]

Adverse effects / adverse reactions

    • (2024): Manzoor R+, J Ayub Med Coll Abbottabad 36(4), 816-820 (59 cases)
    • (2024): Yan H+, Front Pharmacol Feb (e-Collection) [REVIEW]Pediatric
    • (2023): Longo V+, Thorac Cancer Mar, Online ahead of print [REVIEW]
    • (2022): Yan YD+, EClinicalMedicine Aug (e-Collection) [REVIEW]
    • (2021): Kawasumi K+, Mol Clin Oncol 14(1), 12

Adverse fertility effect / decreased fertility / infertility

    • (2023): Lavafian A+, Clin Transl Oncol 25(7), 1893-1905 [REVIEW]

Tooth disorder

    • (2005): Tredwin CJ+, J Dent Res 84(7), 596-602 [REVIEW]Pediatric

Toothache (odontalgia)

    • (2021): Hino S+, Ann Maxillofac Surg 11(1), 86-90 (6 cases)
    • (2010): Zadik Y+, J Endod 36(9), 1588-92

Saved Searches Watched Drugs
Litt's app available free to subscribers

Search drug eruptions and reactions data anytime, anywhere

With full access to drug profiles, reactions and linked PubMed abstracts through your smart phone!

If you subscribe via your institution and do not have a personal login you will need to register on the website to create a login for the app.

Back to top
  • Help
  • Terms & Conditions
  • Privacy
  • Disclaimer
  • Contact us

© 2025 Taylor & Francis Group, LLC. All Rights Reserved.